key: cord-0273640-393lg7sa authors: Driscoll, Joseph R.; Wallace, Tanya L.; Martin, William J.; Margolis, Elyssa B. title: Differential modulation of ventral tegmental area circuits by the nociceptin/orphanin FQ system date: 2019-09-19 journal: bioRxiv DOI: 10.1101/776484 sha: 5ad575c53cdd172368a85bec52ebc3eb4167e294 doc_id: 273640 cord_uid: 393lg7sa The neuropeptide nociceptin/orphanin FQ (N/OFQ) system can be activated under conditions of stress and is associated with disorders of emotional regulation and reward processing. N/OFQ and its cognate receptor, NOP, are highly enriched in dopaminergic pathways, and intra-ventricular agonist delivery decreases dopamine levels in the dorsal striatum, nucleus accumbens (NAc), and the ventral tegmental area (VTA). We used whole cell electrophysiology in acute rat brain slices to investigate synaptic actions of N/OFQ in VTA neurons. Consistent with previous reports, we found that N/OFQ is primarily inhibitory, causing outward currents in both immunocytochemically identified dopaminergic (tyrosine hydroxylase positive (TH(+)) and non-dopaminergic (TH(−)) VTA neurons (effect at 1 μM: 20 ± 4 pA). A smaller population of VTA neurons responded to low dose N/OFQ with small inward currents (effect at 10 nM: −11 ± 2 pA). Application of 100 nM N/OFQ resulted in a markedly diminished response to a second N/OFQ application, consistent with receptor desensitization (14 ± 10% of first response). N/OFQ generated outward currents in VTA neurons that project to the medial prefrontal cortex (mPFC), but inward currents in a subset of VTA neurons that project to posterior anterior cingulate cortex. Interestingly, while N/OFQ inhibited VTA cell bodies that project to the NAc, it had little effect on electrically or optogenetically evoked dopamine released from terminals in the NAc measured ex vivo with fast scan cyclic voltammetry. These results extend our understanding of the N/OFQ system in dopaminergic pathways implicated in many neurobehavioral disorders. Nociceptin/Orphanin FQ (N/OFQ) and its receptor (NOP) make up a neuropeptide Each of these actions must be considered to understand the biological relevance of the 75 nociceptin/NOP system and to guide further research. Recordings were made using an Axopatch 1-D (Axon Instruments, Union City, CA), 92 filtered at 2 kHz, and collected at 20 kHz using IGOR Pro (Wavemetrics, Lake Oswego, OR). Liquid junction potentials were not corrected during recordings. Hyperpolarization-activated 94 cation currents (Ih) were recorded by voltage clamping cells and stepping from -60 to -40, -50, -95 70, -80, -90, -100, -110, and -120 mV. The Ih magnitude was measured as the difference 96 between the initial response to the voltage step after the capacitive peak and the final current 97 response. Pharmacology experiments were completed in voltage-clamp mode (V = -60 mV) to 99 measure changes in membrane current. Series resistance was monitored online by measuring 100 the peak of the capacitance transient in response to a −4 mV voltage step applied at the onset 101 of each sweep. Input resistance was measured using the steady state response to the same 102 voltage step. Upon breaking into the cell, at least 10 min was allowed for the cell to stabilize 103 and for the pipette internal solution to dialyze into the cell. Drugs were applied via bath perfusion 104 at a flow rate of 2 mL/min or pressure ejection nearby the recorded cell (within ~200 µm) using a 105 SmartSquirt micro-perfusion system (AutoMate Scientific, Berkeley, CA). N/OFQ (1 nM to 10 106 M) was bath applied (5-7 min) only after a 5-min stable baseline was achieved. To test that 107 observed N/OFQ-mediated effects were specific to NOP, the selective NOP antagonist BTRX-108 246040 (10 or 100 nM) was applied for 10 min prior to N/OFQ. Stock solutions of drugs were made in advance, stored at -20°C, and diluted into aCSF −4.0 from skull surface), the pACC (AP, -1.6; ML, ± 0.6; V, −3.5), or the NAc (AP, +1.5; ML, ± 118 0.8; V, −6.7). Neuro-DiI (7% in ethanol; Biotium) was slowly injected, 50.6 nL per side. Animals 119 were allowed to recover for 5 to 7 days while the retrograde tracer transported back to the cell 120 bodies. On the day of recording, the experimenter was blinded to the location of retrograde 121 tracer injection (mPFC, pACC, or NAc) and slices were prepared as above. Projection neurons 122 were chosen by selecting cells observed as labeled using epiflorescent illumination. All injection 123 sites were histologically confirmed by a third party blinded to the results to avoid bias. N/OFQ 124 responses were analyzed prior to unblinding. Animals with improper injection placements or 125 significant diffusion outside of the target region were rejected. Immunohistochemistry: Slices were pre-blocked for 2 h at room temperature in PBS with 127 0.2% BSA and 5% normal goat serum, then incubated at 4°C with a rabbit anti-TH polyclonal To confirm responses were due to activation of the NOP and were not off-target effects, and TH(-) cells (Fig. 5D ). Half of NAc-projecting VTA neurons (7/14) responded to N/OFQ with outward currents (9 240 ± 1 pA; Fig. 5C,D) . No excitations were observed in this projection. Of the 7 NAc-projecting 241 neurons that responded to N/OFQ, 2 were confirmed TH(+) and 3 were TH(-) (Fig. 5D ). Together, these data indicate that similar N/OFQ inhibitory effects occur in VTA neurons that 243 project to mPFC and NAc, but these effects are opposed to those on VTA projections to pACC, 244 some of which responded to N/OFQ with an inward current. The results presented here demonstrate that N/OFQ affects both dopaminergic and non- One provocative possibility is that it is this degradation of working memory function that is the 385 primary mechanism underlying the lack of place conditioning in response to central N/OFQ, 386 rather than that this treatment is affectively neutral. This interpretation is consistent with work showing that N/OFQ blocks opioid induced conditioned place preference yet has no effect on 388 opioid self-administration as well (Sakoori and Murphy 2004; Walker et al. 1998 ). The results of this study extend our understanding of the NOP system biology and 390 provide considerations for additional investigation into NOP function within limbic circuits. These findings clarify that strong NOP desensitization occurs in neurons at moderate Ventral tegmental area: cellular heterogeneity, connectivity and 587 behaviour Interactions between sulpiride infusions within the perifornical region 589 of the lateral hypothalamus and the nucleus accumbens on measures of locomotor activity and 590 conditioned place preference Intracerebroventricular orphanin FQ/Nociceptin supresses 592 dopamine release in the nucleus accumbens of anaesthetized rats Orphanin FQ/Nociceptin Modulation of Mesolimbic Dopamine 594 Transmission Determined by Microdialysis Circadian-Dependent Learning and 596 Memory Enhancement in Nociceptin Receptor-Deficient Mice with a Novel KUROBOX 597 Apparatus Using Stress-Free Positive Cue Task Effect of stress on hippocampal 599 nociceptin expression in the rat Opioid receptor-601 like (ORL1) receptor distribution in the rat central nervous system: comparison of ORL1 602 receptor mRNA expression with (125)I-[(14)Tyr]-orphanin FQ binding The ORL1 Receptor: Molecular Pharmacology and Signalling Mechanisms Orphanin FQ-induced hyperphagia is mediated by 607 corticosterone and central glucocorticoid receptors Naturally occurring opioid receptor agonists stimulate adenylate cyclase 611 activity in rat olfactory bulb Dopamine and Cognitive Control in Prefrontal Cortex A Paranigral VTA Nociceptin Circuit that Constrains Motivation for 617 Reward Prefrontal Dopamine in Associative Learning and Memory Effect of morphine sulfate on adenylate cyclase and 621 phosphodiesterase activities in rat corpus striatum VTA glutamatergic inputs 623 to nucleus accumbens drive aversion by acting on GABAergic interneurons Structure-Activity Relationship Studies on the 626 Novel Neuropeptide Orphanin FQ Orphanin FQ: A Neuropeptide That Activates an Opioidlike G 629 Protein-Coupled Receptor Reduces Ethanol Self-Administration and Ethanol Seeking in Animal Models Central administration of nociceptin/orphanin FQ blocks the acquisition 636 of conditioned place preference to morphine and cocaine, but not conditioned place aversion 637 to naloxone in mice Nociceptin/orphanin FQ modulates spatial learning via ORL-1 639 receptors in the dorsal hippocampus of the rat Involvement of the mesolimbic dopamine system in mediating 641 the aversive effects of opioid antagonists in the rat Neuroanatomical substrates mediating the 643 aversive effects of D-1 dopamine receptor antagonists Identification of opioid receptor-like (ORL1) peptide-stimulated 646 [35S]GTP gamma S binding in rat brain Agonist-induced internalization and 648 desensitization of the human nociceptin receptor expressed in CHO cells Nociceptin-induced internalization of the ORL1 receptor in 651 human neuroblastoma cells Opposing tonically active endogenous opioid systems 653 modulate the mesolimbic dopaminergic pathway Nicotine-conditioned single-trial place 656 preference: selective role of nucleus accumbens shell dopamine D1 receptors in acquisition Induction of G protein-coupled receptor kinases 2 and 3 contributes 659 to the cross-talk between μ and ORL1 receptors following prolonged agonist exposure Discovery of a novel series of orally active nociceptin/orphanin FQ (NOP) 664 receptor antagonists based on a dihydrospiro Ligands, Functions, and Interactions with Opioid Systems Phasic firing in 670 dopaminergic neurons is sufficient for behavioral conditioning Pharmacology and behavioral pharmacology of the mesocortical dopamine 672 system Stereotaxic mapping of the monoamine pathways in the rat brain The Anxiolytic-Like 677 Effects of the Novel Increase by the ORL1 receptor (opioid receptor-like1) ligand, 681 nociceptin, of inwardly rectifying K conductance in dorsal raphe nucleus neurones N/OFQ into the nucleus accumbens shell blocks cocaine-induced increases in extracellular 685 dopamine and locomotor activity Anxiolytic-like effects of nociceptin/orphanin 687 FQ in the elevated plus maze and in the conditioned defensive burying test in rats Nociceptin fails to affect heroin self-administration in 690 the rat cDNA Cloning of 692 an orphan opiate receptor gene family member and its splice variant Kappa receptor regulation of 695 dopamine release from striatum and cortex of rats and guinea pigs Dopamine in the prefrontal cortex regulates rats 698 behavioral flexibility to changing reward value Forebrain substrates of reward and motivation Therapeutic Approaches for NOP Receptor Antagonists in 701 Neurobehavioral Disorders: Clinical Studies in Major Depressive Disorder and Alcohol Use 702 Disorder with BTRX-246040 (LY2940094) Recombinase-driver rat lines: 705 tools, techniques, and optogenetic application to dopamine-mediated reinforcement Serine 363 Is Required for Nociceptin/Orphanin FQ Opioid Receptor (NOPR) Desensitization Actions of orphanin FQ/nociceptin on rat ventral tegmental 711 area neurons in vitro